GlassScriptPhysician profile
Ralph Aquila
NPI 1497814396
$143,157.74
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $14K · 2021: $27K · 2022: $19K · 2024: $18K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $2,088 · Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,439.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,623.00 |
| Travel and Lodging | $2,088.34 |
| Food and Beverage | $731.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34,832.83 | 2024-2025 | Cobenfy |
| H. Lundbeck A S | $34,714.31 | 2019 | |
| Alkermes, INC. | $33,270.19 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21,811.74 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $7,615.41 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $3,312.75 | 2020-2021 | |
| Lundbeck LLC | $2,305.71 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,248.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $1,623.80 | 2019-2020 | |
| Noven Pharmaceuticals, INC. | $797.00 | 2020 | |
| Neurocrine Biosciences, INC. | $555.20 | 2019 | |
| Eli Lilly and Company | $30.39 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.01 | 2019 | |
| Abbvie INC. | $19.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Aquila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.